Drug Therapy in the Heart Transplant Recipient
نویسندگان
چکیده
منابع مشابه
Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs.
Part I of this series describes the mechanisms and types of rejection and the intravenous immunosuppressive drugs commonly used for induction or antirejection therapy. In this article, we review the commonly used oral immunosuppressive drugs. Intravenous corticosteroid methylprednisolone is included in the discussion of corticosteroids. Table 1 gives trade names, pharmacology, necessary adjustm...
متن کاملDrug therapy in the heart transplant recipient: part I: cardiac rejection and immunosuppressive drugs.
Survival after heart transplantation has improved considerably over the past 20 years. Half of all patients now live 9 years, and 25% live 17 years.1 Currently, 20 000 heart transplant recipients live in the United States.2 Improved longevity means prolonged immunosuppression and the concomitant use of drugs to prevent or treat the long-term complications of immunosuppressive agents, such as in...
متن کاملDrug therapy in the heart transplant recipient: Part III: common medical problems.
Continued improvement in the long-term survival of heart transplant recipients has resulted in a population of patients with prolonged exposure to immunosuppressive drugs.1 This exposure, coupled with the increasing age of recipients, has resulted in an impressive prevalence of comorbidities in these patients. Indeed, by 5 years after transplantation, 95% of recipients have hypertension, 81% ha...
متن کاملCryptococcal cellulitis in a heart transplant recipient
CNS: central nervous system INTRODUCTION Cryptococcosis is an invasive fungal infection most often caused by the encapsulated yeasts Cryptococcus neoformans and Cryptococcus gattii. C neoformans is the major pathogenic member of the genus, thought to account for approximately 80% of isolates worldwide, and is found in pigeon droppings, soil, and rotting vegetation. The incidence in the United S...
متن کاملFear of rejection--monitoring the heart-transplant recipient.
Among patients undergoing heart transplantation, a fundamental clinical concern is the risk of rejection of the new organ. Although modern immunosuppressive regimens have reduced the incidence of rejection substantially, about one quarter of recipients will still have a rejection episode requiring treatment during the first year after transplantation.1 Acute rejection is the cause of 12% of dea...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation
سال: 2005
ISSN: 0009-7322,1524-4539
DOI: 10.1161/01.cir.0000151609.60618.3c